Duan Jiahua, Qian Gaofei, Zhang Huikang, Wang Feifan, Tian Qiang, Lei Dong, Zhao Jianning
Nanjing Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, 210023, P. R. China.
State Key Laboratory of Pharmaceutical Biotechnology, School of Life Sciences, Nanjing University, Nanjing, 210023, P. R. China.
Adv Sci (Weinh). 2025 Jun;12(21):e2414362. doi: 10.1002/advs.202414362. Epub 2025 Mar 27.
A central focus of bone tissue engineering is the construction of vascular systems, which provide nutrients for cell survival, remove metabolic waste, and accelerate tissue regeneration. Platelet-derived growth factor-BB (PDGFB) has the ability to stimulate both vascularization and bone regeneration; however, its clinical application has been hindered by side effects and low efficacy due to suboptimal delivery systems. In this study, a biomimetic vascular scaffold crosslinked with heparan sulfate (HS) is developed to enable sustained delivery of the PDGFB-LG4 fusion protein, targeting the regeneration of critically sized bone defects. The scaffold is designed with a vascular-like hierarchical structure, incorporating a customized 3D framework, multibranched microchannels, and permeable porous walls, which facilitates mass exchange and cell infiltration. PDGFB-LG4 exhibits superior osteoinductive and angiogenic activity compared to PDGFB. In a calvarial defect model, the composite scaffold (PCLHS-PDGFB-LG4) significantly enhances both vascularization and bone regeneration, demonstrating improved efficacy at lower doses compared to PDGFB. This approach may be applicable to other growth factors and gelatin-based materials, offering the potential for a wide range of applications in regenerative medicine.
骨组织工程的一个核心重点是血管系统的构建,该系统为细胞存活提供营养、清除代谢废物并加速组织再生。血小板衍生生长因子-BB(PDGFB)具有刺激血管生成和骨再生的能力;然而,由于递送系统不理想,其副作用和低疗效阻碍了其临床应用。在本研究中,开发了一种与硫酸乙酰肝素(HS)交联的仿生血管支架,以实现PDGFB-LG4融合蛋白的持续递送,靶向临界尺寸骨缺损的再生。该支架设计有类似血管的分层结构,包含定制的三维框架、多分支微通道和可渗透的多孔壁,有助于物质交换和细胞浸润。与PDGFB相比,PDGFB-LG4表现出卓越的骨诱导和血管生成活性。在颅骨缺损模型中,复合支架(PCLHS-PDGFB-LG4)显著增强了血管生成和骨再生,与PDGFB相比,在较低剂量下显示出更高的疗效。这种方法可能适用于其他生长因子和基于明胶的材料,为再生医学中的广泛应用提供了潜力。